Oddo BHF - Morning CrÃ©dit 05/03/2018

Report

Oddo BHF

Carole Braudeau

Morning CrÃ©dit 05/03/2018

AXA annonce ce matin lâ€™acquisition de XL Group pour 15.3 mds USD en cashElections italiennesÂ : les rÃ©sultats prÃ©liminaires devraient dÃ©boucher sur de longues et complexes nÃ©gociations afin de former un Ã©ventuel gouvernement>

05/03/2018 15 FR

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Analysts

Carole Braudeau

Other Reports from Oddo BHF

Matthias Desmarais

Matthias Desmarais

Oddo’s 2 Weeks Ahead_Friday 24 October 2025

17h / 56m 17h / 56m 1 EN

Matthias Desmarais

Matthias Desmarais

Oddo’s 2 Weeks Ahead_Vendredi 24 Octobre 2025

19h / 58m 19h / 58m 1 FR

Martial Descoutures

Martial Descoutures

Sanofi : Un très solide T3; résultats de tolebrutinib en PPMS toujours au T4

20h / 13m 20h / 13m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning CrÃ©dit 05/03/2018

Oddo’s 2 Weeks Ahead_Friday 24 October 2025

Oddo’s 2 Weeks Ahead_Vendredi 24 Octobre 2025

Sanofi : Un très solide T3; résultats de tolebrutinib en PPMS toujours au T4

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe